Matching articles for "Bydureon BCise"

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • August 5, 2024;  (Issue 1708)
...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3 | Show Full IntroductionHide Full Introduction

In Brief: GI Effects of GLP-1 Receptor Agonists

   
The Medical Letter on Drugs and Therapeutics • November 27, 2023;  (Issue 1690)
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2...
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes and weight management (see Table 1), but they delay gastric emptying and commonly cause nausea and vomiting. Gastroparesis and bowel obstruction (ileus) have also been reported with their use.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):191-2 | Show Full IntroductionHide Full Introduction

Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)

   
The Medical Letter on Drugs and Therapeutics • August 21, 2023;  (Issue 1683)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone (Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone (Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and extended-release exenatide (Bydureon BCise) are also approved for use in children ≥10 years old.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e137 | Show Full IntroductionHide Full Introduction